论文部分内容阅读
1.前言近年来,由于遗传工程的进步,给机体高分子的应用带来了两项技术革新。其一,可使用大肠杆菌等微生物,进行体内含量极低的机体分子的工业化生产。结果能得到与机体制造的物质完全相同的人造物质,如果将其给予该物质缺乏或不足引起严重功能障碍的患者即可缓解其症状。第二,是可将天然存在的机体高分子在基因水平上加以改变,使其超过原有活性功能,即进行“高效化”的试验。这些方法虽然刚有头绪,但已可预期其将涌现种种有价值的成果。本文拟介绍作者进行的高效化血栓溶解药前尿激酶的试验。
1. Introduction In recent years, thanks to advances in genetic engineering, two technological innovations have been brought to the application of body polymers. First, Escherichia coli and other microorganisms can be used to carry out industrial production of body molecules with extremely low contents in the body. As a result, an artificial substance identical to that produced by the body can be obtained, and the symptoms of the same can be alleviated by giving it to a patient suffering from severe dysfunction if the substance is deficient or insufficient. Second, it is possible to change the naturally occurring macromolecules at the genetic level to make them surpass their original active function, ie to carry out “efficient” experiments. Although these approaches are just beginning to take shape, it is anticipated that there will be many valuable achievements. This article is intended to introduce the author’s trial of highly effective thrombolytic prodromal urokinase.